EP Patent

EP0555478A1 — Pyrimidine derivative and medicine

Assigned to Nippon Shinyaku Co Ltd · Expires 1993-08-18 · 33y expired

What this patent protects

The invention aims at obtaining a novel compound which is excellent in central nervous system selectivity and reduced in side effects and has an activity of improving the function of learning and memory, thus providing an excellent medicine for dementia. The invention relates to …

USPTO Abstract

The invention aims at obtaining a novel compound which is excellent in central nervous system selectivity and reduced in side effects and has an activity of improving the function of learning and memory, thus providing an excellent medicine for dementia. The invention relates to a compound represented by general formula (I), a pharmacologically acceptable salt thereof, and an agent for remedying the disturbance of learning and memory containing the same as the active ingredient of formula (I), wherein R¹ and R² may be the same or different from each other and each represents hydrogen, hydroxy, alkoxy, trifluoromethyl or halogen; A represents methyl, trifluoromethyl or tertbutyl; and Y represents O or NH.

Drugs covered by this patent

Patent Metadata

Patent number
EP0555478A1
Jurisdiction
EP
Classification
Expires
1993-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Nippon Shinyaku Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.